

Harry J G M Crijns

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7695057/publications.pdf>

Version: 2024-02-01

162
papers

31,573
citations

36203

51
h-index

7496

151
g-index

162
all docs

162
docs citations

162
times ranked

18733
citing authors

#	ARTICLE	IF	CITATIONS
1	Refining Clinical Risk Stratification for Predicting Stroke and Thromboembolism in Atrial Fibrillation Using a Novel Risk Factor-Based Approach. <i>Chest</i> , 2010, 137, 263-272.	0.4	5,657
2	2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). <i>European Heart Journal</i> , 2021, 42, 373-498.	1.0	5,583
3	A Novel User-Friendly Score (HAS-BLED) To Assess 1-Year Risk of Major Bleeding in Patients With Atrial Fibrillation. <i>Chest</i> , 2010, 138, 1093-1100.	0.4	3,810
4	A Comparison of Rate Control and Rhythm Control in Patients with Recurrent Persistent Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2002, 347, 1834-1840.	13.9	2,159
5	Guidelines for the management of atrial fibrillation. <i>Europace</i> , 2010, 12, 1360-1420.	0.7	1,360
6	Early Rhythm-Control Therapy in Patients with Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2020, 383, 1305-1316.	13.9	1,071
7	Effect of Dronedaron on Cardiovascular Events in Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2009, 360, 668-678.	13.9	1,029
8	Lenient versus Strict Rate Control in Patients with Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2010, 362, 1363-1373.	13.9	851
9	Atrial fibrillation management: a prospective survey in ESC Member Countries. <i>European Heart Journal</i> , 2005, 26, 2422-2434.	1.0	770
10	Dronedaron for Maintenance of Sinus Rhythm in Atrial Fibrillation or Flutter. <i>New England Journal of Medicine</i> , 2007, 357, 987-999.	13.9	597
11	Progression From Paroxysmal to Persistent Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2010, 55, 725-731.	1.2	579
12	Evaluation of the Accuracy of Gadolinium-Enhanced Cardiovascular Magnetic Resonance in the Diagnosis of Cardiac Sarcoidosis. <i>Journal of the American College of Cardiology</i> , 2005, 45, 1683-1690.	1.2	519
13	Effect of rate or rhythm control on quality of life in persistent atrial fibrillation. <i>Journal of the American College of Cardiology</i> , 2004, 43, 241-247.	1.2	429
14	Duration of device-detected subclinical atrial fibrillation and occurrence of stroke in ASSERT. <i>European Heart Journal</i> , 2017, 38, 1339-1344.	1.0	428
15	Nurse-led care vs. usual care for patients with atrial fibrillation: results of a randomized trial of integrated chronic care vs. routine clinical care in ambulatory patients with atrial fibrillation. <i>European Heart Journal</i> , 2012, 33, 2692-2699.	1.0	318
16	Dronedaron for prevention of atrial fibrillation: A dose-ranging study. <i>European Heart Journal</i> , 2003, 24, 1481-1487.	1.0	295
17	Prognosis, disease progression, and treatment of atrial fibrillation patients during 1 year: follow-up of the Euro Heart Survey on Atrial Fibrillation. <i>European Heart Journal</i> , 2008, 29, 1181-1189.	1.0	247
18	Analysis of Stroke in ATHENA: A Placebo-Controlled, Double-Blind, Parallel-Arm Trial to Assess the Efficacy of Dronedaron 400 mg BID for the Prevention of Cardiovascular Hospitalization or Death From Any Cause in Patients With Atrial Fibrillation/Atrial Flutter. <i>Circulation</i> , 2009, 120, 1174-1180.	1.6	228

#	ARTICLE	IF	CITATIONS
19	2019 Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous cardiovascular interventions: a joint consensus document of the European Heart Rhythm Association (EHRA), European Society of Cardiology Working Group on Thrombosis, European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm So. Europace, 2019, 21, 192-193.	0.7	209
20	Targeted therapy of underlying conditions improves sinus rhythm maintenance in patients with persistent atrial fibrillation: results of the RACE 3 trial. European Heart Journal, 2018, 39, 2987-2996.	1.0	203
21	Searching for Atrial Fibrillation Poststroke. Circulation, 2019, 140, 1834-1850.	1.6	184
22	Thrombospondin-2 Is Essential for Myocardial Matrix Integrity. Circulation Research, 2004, 95, 515-522.	2.0	179
23	Rate control versus rhythm control for patients with persistent atrial fibrillation with mild to moderate heart failure: Results from the RATE Control versus Electrical cardioversion (RACE) study. American Heart Journal, 2005, 149, 1106-1111.	1.2	177
24	Early and comprehensive management of atrial fibrillation: executive summary of the proceedings from the 2nd AFNET-EHRA consensus conference "research perspectives in AF"™. European Heart Journal, 2009, 30, 2969-2980.	1.0	173
25	Real-Life Observations of Clinical Outcomes With Rhythm- and Rate-Control Therapies for Atrial Fibrillation. Journal of the American College of Cardiology, 2011, 58, 493-501.	1.2	159
26	Cardiac Involvement in Patients With Pulmonary Sarcoidosis Assessed at Two University Medical Centers in the Netherlands. Chest, 2005, 128, 30-35.	0.4	143
27	Rate control in atrial fibrillation. Lancet, The, 2016, 388, 818-828.	6.3	140
28	Idiopathic Left Bundle-Branch Block "Shaped Ventricular Tachycardia May Originate Above the Pulmonary Valve. Circulation, 2003, 108, 1960-1967.	1.6	128
29	Pharmacologic versus direct-current electrical cardioversion of atrial flutter and fibrillation. American Journal of Cardiology, 1999, 84, 147-151.	0.7	120
30	Acute Results of Transvenous Cryoablation of Supraventricular Tachycardia (Atrial Fibrillation,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 307 Journal of Cardiovascular Electrophysiology, 2002, 13, 1082-1089.	0.8	120
31	Early or Delayed Cardioversion in Recent-Onset Atrial Fibrillation. New England Journal of Medicine, 2019, 380, 1499-1508.	13.9	120
32	Clinical correlates of immediate success and outcome at 1-year follow-up of real-world cardioversion of atrial fibrillation: the Euro Heart Survey. Europace, 2012, 14, 666-674.	0.7	114
33	Early Rhythm Control Therapy in Patients With Atrial Fibrillation and Heart Failure. Circulation, 2021, 144, 845-858.	1.6	111
34	The Additional Value of Gadolinium-Enhanced MRI to Standard Assessment for Cardiac Involvement in Patients With Pulmonary Sarcoidosis. Chest, 2005, 128, 1629-1637.	0.4	108
35	Efficacy, Safety, and Determinants of Conversion of Atrial Fibrillation and Flutter With Oral Amiodarone. American Journal of Cardiology, 1997, 79, 53-57.	0.7	106
36	Randomized Study Comparing Radiofrequency Ablation With Cryoablation for the Treatment of Atrial Flutter With Emphasis on Pain Perception. Circulation, 2003, 107, 1250-1252.	1.6	106

#	ARTICLE	IF	CITATIONS
37	Atrial Fibrillation and Heart Failure in Cardiology Practice: Reciprocal Impact and Combined Management From the Perspective of Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2009, 53, 1690-1698.	1.2	98
38	Tailored telemonitoring in patients with heart failure: results of a multicentre randomized controlled trial. <i>European Journal of Heart Failure</i> , 2012, 14, 791-801.	2.9	96
39	Lenient vs. strict rate control in patients with atrial fibrillation and heart failure: a post-hoc analysis of the RACE II study. <i>European Journal of Heart Failure</i> , 2013, 15, 1311-1318.	2.9	88
40	Systematic, early rhythm control strategy for atrial fibrillation in patients with or without symptoms: the EAST-AFNET 4 trial. <i>European Heart Journal</i> , 2022, 43, 1219-1230.	1.0	84
41	Contemporary real life cardioversion of atrial fibrillation: Results from the multinational RHYTHM-AF study. <i>International Journal of Cardiology</i> , 2014, 172, 588-594.	0.8	83
42	Catheter-Based Cryoablation Permanently Cures Patients With Common Atrial Flutter. <i>Circulation</i> , 2004, 109, 1636-1639.	1.6	80
43	QRS Area Is a Strong Determinant of Outcome in Cardiac Resynchronization Therapy. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2018, 11, e006497.	2.1	69
44	Heart failure in patients with atrial fibrillation in Europe: a report from the EURObservational Research Programme Pilot survey on Atrial Fibrillation. <i>European Journal of Heart Failure</i> , 2015, 17, 570-582.	2.9	68
45	Continuous vs Episodic Prophylactic Treatment With Amiodarone for the Prevention of Atrial Fibrillation. <i>JAMA - Journal of the American Medical Association</i> , 2008, 300, 1784.	3.8	66
46	Coronary Angiography After Cardiac Arrest Without ST Segment Elevation. <i>JAMA Cardiology</i> , 2020, 5, 1358.	3.0	65
47	Implementation of an on-demand app-based heart rate and rhythm monitoring infrastructure for the management of atrial fibrillation through teleconsultation: TeleCheck-AF. <i>Europace</i> , 2021, 23, 345-352.	0.7	65
48	Nurse-led vs. usual-care for atrial fibrillation. <i>European Heart Journal</i> , 2020, 41, 634-641.	1.0	64
49	Aortic elongation part I: the normal aortic ageing process. <i>Heart</i> , 2018, 104, 1772-1777.	1.2	63
50	The Increasing Role of Rhythm Control in Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2022, 79, 1932-1948.	1.2	63
51	Initial Imaging-Guided Strategy Versus Routine Care in Patients With Non-ST-Segment Elevation Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2019, 74, 2466-2477.	1.2	58
52	Cardioversion of atrial fibrillation and atrial flutter revisited: current evidence and practical guidance for a common procedure. <i>Europace</i> , 2020, 22, 1149-1161.	0.7	58
53	Effect of nebivolol on outcome in elderly patients with heart failure and atrial fibrillation: insights from SENIORS. <i>European Journal of Heart Failure</i> , 2012, 14, 1171-1178.	2.9	57
54	The atrial fibrillation knowledge scale: Development, validation and results. <i>International Journal of Cardiology</i> , 2013, 168, 1422-1428.	0.8	57

#	ARTICLE	IF	CITATIONS
55	The European TeleCheck-AF project on remote app-based management of atrial fibrillation during the COVID-19 pandemic: centre and patient experiences. <i>Europace</i> , 2021, 23, 1003-1015.	0.7	56
56	Indices of bipolar complex fractionated atrial electrograms correlate poorly with each other and atrial fibrillation substrate complexity. <i>Heart Rhythm</i> , 2015, 12, 1415-1423.	0.3	52
57	Glomerular filtration rate in patients with atrial fibrillation and 1-year outcomes. <i>Scientific Reports</i> , 2016, 6, 30271.	1.6	51
58	Radiofrequency Catheter Ablation of Idiopathic Ventricular Tachycardia Originating in the Main Stem of the Pulmonary Artery. <i>Journal of Cardiovascular Electrophysiology</i> , 2002, 13, 281-284.	0.8	50
59	Computational models of atrial fibrillation: achievements, challenges, and perspectives for improving clinical care. <i>Cardiovascular Research</i> , 2021, 117, 1682-1699.	1.8	47
60	Right ventricular involvement and the extent of left ventricular enhancement with magnetic resonance predict adverse outcome in pulmonary sarcoidosis. <i>ESC Heart Failure</i> , 2018, 5, 157-171.	1.4	46
61	Chronic obstructive pulmonary disease and atrial fibrillation: an interdisciplinary perspective. <i>European Heart Journal</i> , 2021, 42, 532-540.	1.0	46
62	The ECG as a tool to determine atrial fibrillation complexity. <i>Heart</i> , 2014, 100, 1077-1084.	1.2	45
63	Hybrid versus catheter ablation in patients with persistent and longstanding persistent atrial fibrillation: a systematic review and meta-analysis. <i>European Journal of Cardio-thoracic Surgery</i> , 2019, 56, 433-443.	0.6	44
64	Comparison of a non-invasive arterial pulse contour technique and echo Doppler aorta velocity-time integral on stroke volume changes in optimization of cardiac resynchronization therapy. <i>Europace</i> , 2011, 13, 87-95.	0.7	42
65	Research Priorities in Atrial Fibrillation Screening. <i>Circulation</i> , 2021, 143, 372-388.	1.6	42
66	Regional differences in presentation and treatment of patients with atrial fibrillation in Europe: a report from the EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry. <i>Europace</i> , 2015, 17, 194-206.	0.7	41
67	EHRA White Paper: knowledge gaps in arrhythmia management—status 2019. <i>Europace</i> , 2019, 21, 993-994.	0.7	40
68	Idiopathic atrial fibrillation revisited in a large longitudinal clinical cohort. <i>Europace</i> , 2012, 14, 184-190.	0.7	39
69	Atrial fibrillation progression risk factors and associated cardiovascular outcome in well-phenotyped patients: data from the AF-RISK study. <i>Europace</i> , 2020, 22, 352-360.	0.7	39
70	Dynamic risk assessment to improve quality of care in patients with atrial fibrillation: the 7th AFNET/EHRA Consensus Conference. <i>Europace</i> , 2021, 23, 329-344.	0.7	38
71	Factor XIa and Thrombin Generation Are Elevated in Patients with Acute Coronary Syndrome and Predict Recurrent Cardiovascular Events. <i>PLoS ONE</i> , 2016, 11, e0158355.	1.1	37
72	Both Prediabetes and Type 2 Diabetes Are Associated With Lower Heart Rate Variability: The Maastricht Study. <i>Diabetes Care</i> , 2020, 43, 1126-1133.	4.3	35

#	ARTICLE	IF	CITATIONS
73	Temporal patterns and short-term progression of paroxysmal atrial fibrillation: data from RACE V. <i>Europace</i> , 2020, 22, 1162-1172.	0.7	35
74	Presenting Pattern of Atrial Fibrillation and Outcomes of Early Rhythm Control Therapy. <i>Journal of the American College of Cardiology</i> , 2022, 80, 283-295.	1.2	34
75	Integrated specialized atrial fibrillation clinics reduce all-cause mortality: post hoc analysis of a randomized clinical trial. <i>Europace</i> , 2019, 21, 1785-1792.	0.7	33
76	Right ventricular involvement in cardiac sarcoidosis demonstrated with cardiac magnetic resonance. <i>ESC Heart Failure</i> , 2017, 4, 535-544.	1.4	32
77	Nightly sleep apnea severity in patients with atrial fibrillation: Potential applications of long-term sleep apnea monitoring. <i>IJC Heart and Vasculature</i> , 2019, 24, 100424.	0.6	32
78	Electrical Remodeling and Atrial Dilation During Atrial Tachycardia are Influenced by Ventricular Rate: Role of Developing Tachycardiomyopathy. <i>Journal of Cardiovascular Electrophysiology</i> , 2001, 12, 1404-1410.	0.8	31
79	Management and prognosis of atrial fibrillation in diabetic patients: an EORP-AF General Pilot Registry report. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2018, 4, 172-179.	1.4	31
80	The influence of progression of atrial fibrillation on quality of life: a report from the Euro Heart Survey. <i>Europace</i> , 2018, 20, 929-934.	0.7	30
81	Clinical assessment of aortic valve stenosis: Comparison between 4D flow MRI and transthoracic echocardiography. <i>Journal of Magnetic Resonance Imaging</i> , 2020, 51, 472-480.	1.9	30
82	Symptom severity is associated with cardiovascular outcome in patients with permanent atrial fibrillation in the RACE II study. <i>Europace</i> , 2014, 16, 1417-1425.	0.7	29
83	Symptomatic atrial fibrillation and risk of cardiovascular events: data from the Euro Heart Survey. <i>Europace</i> , 2017, 19, 1922-1929.	0.7	27
84	Long-term outcomes of cryoballoon-based left atrial appendage isolation in addition to pulmonary vein isolation in persistent atrial fibrillation. <i>Europace</i> , 2019, 21, 1653-1662.	0.7	24
85	Maastricht antiarrhythmic drug evaluator (MANTA): A computational tool for better understanding of antiarrhythmic drugs. <i>Pharmacological Research</i> , 2019, 148, 104444.	3.1	24
86	Bicuspid Aortic Valve Stenosis and the Effect of Vitamin K2 on Calcification Using 18F-Sodium Fluoride Positron Emission Tomography/Magnetic Resonance: The BASIK2 Rationale and Trial Design. <i>Nutrients</i> , 2018, 10, 386.	1.7	22
87	Sex-related differences in risk factors, outcome, and quality of life in patients with permanent atrial fibrillation: results from the RACE II study. <i>Europace</i> , 2020, 22, 1619-1627.	0.7	22
88	Anticoagulation, therapy of concomitant conditions, and early rhythm control therapy: a detailed analysis of treatment patterns in the EAST - AFNET 4 trial. <i>Europace</i> , 2022, 24, 552-564.	0.7	22
89	Recent Advances in Drug Therapy for Atrial Fibrillation. <i>Journal of Cardiovascular Electrophysiology</i> , 2003, 14, S40-S47.	0.8	21
90	RHYTHM-AF: design of an international registry on cardioversion of atrial fibrillation and characteristics of participating centers. <i>BMC Cardiovascular Disorders</i> , 2012, 12, 85.	0.7	19

#	ARTICLE	IF	CITATIONS
91	Targeted therapy of underlying conditions improves quality of life in patients with persistent atrial fibrillation: results of the RACE 3 study. <i>Europace</i> , 2019, 21, 563-571.	0.7	19
92	Abnormalities in myocardial contractility, metabolism and perfusion reserve in non-stenotic coronary segments in heart failure patients. <i>Cardiovascular Research</i> , 2002, 55, 97-103.	1.8	18
93	The electrocardiogram as a predictor of successful pharmacological cardioversion and progression of atrial fibrillation. <i>Europace</i> , 2018, 20, e96-e104.	0.7	17
94	The prognostic impact of mechanical atrial dysfunction and atrial fibrillation in heart failure with preserved ejection fraction. <i>European Heart Journal Cardiovascular Imaging</i> , 2021, 23, 74-84.	0.5	17
95	Dronedaron for the Treatment of Atrial Fibrillation with Concomitant Heart Failure with Preserved and Mildly Reduced Ejection Fraction: Post-Hoc Analysis of the ATHENA Trial. <i>European Journal of Heart Failure</i> , 2022, , .	2.9	17
96	Gradual increase in thrombogenicity of juvenile platelets formed upon offset of prasugrel medication. <i>Haematologica</i> , 2015, 100, 1131-1138.	1.7	16
97	Rate control drugs differ in the prevention of progression of atrial fibrillation. <i>Europace</i> , 2022, 24, 384-389.	0.7	14
98	Clinical correlates of echocardiographic tissue velocity imaging abnormalities of the left atrial wall during atrial fibrillation. <i>Europace</i> , 2014, 16, 1546-1553.	0.7	13
99	The Biomarkers NT-proBNP and CA-125 are Elevated in Patients with Idiopathic Atrial Fibrillation. <i>Journal of Atrial Fibrillation</i> , 2018, 11, 2058.	0.5	13
100	Quantification of epicardial adipose tissue in patients undergoing hybrid ablation for atrial fibrillation. <i>European Journal of Cardio-thoracic Surgery</i> , 2019, 56, 79-86.	0.6	13
101	Stabilization patterns and variability of hs-CRP, NT-proBNP and ST2 during 1 year after acute coronary syndrome admission: results of the BIOMArCS study. <i>Clinical Chemistry and Laboratory Medicine</i> , 2020, 58, 2099-2106.	1.4	13
102	Atrial Fibrillatory Wall Motion and Degree of Atrial Remodeling in Patients with Atrial Fibrillation: A Tissue Velocity Imaging Study. <i>Journal of Cardiovascular Electrophysiology</i> , 2009, 20, 1374-1381.	0.8	12
103	Clinical and electrophysiological predictors of device-detected new-onset atrial fibrillation during 3 years after cardiac surgery. <i>Europace</i> , 2021, 23, 1922-1930.	0.7	12
104	Effect of continuous versus episodic amiodarone treatment on quality of life in persistent atrial fibrillation. <i>Europace</i> , 2010, 12, 785-791.	0.7	11
105	The role of cardiovascular magnetic resonance imaging and computed tomography angiography in suspected non- σ ST-elevation myocardial infarction patients: Design and rationale of the CARdiovascular Magnetic rEsonance imaging and computed Tomography Angiography (CARMENTA) trial. <i>American Heart Journal</i> , 2013, 166, 968-975.	1.2	11
106	Acute cardioversion vs a wait-and-see approach for recent-onset symptomatic atrial fibrillation in the emergency department: Rationale and design of the randomized ACWAS trial. <i>American Heart Journal</i> , 2017, 183, 49-53.	1.2	11
107	Risk Factors for Atrial Fibrillation Progression. <i>Cardiac Electrophysiology Clinics</i> , 2021, 13, 201-209.	0.7	11
108	Both beat-to-beat changes in RR-interval and left ventricular filling time determine ventricular function during atrial fibrillation. <i>Europace</i> , 2021, 23, i21-i28.	0.7	11

#	ARTICLE	IF	CITATIONS
109	Antiarrhythmic drugs in patients with early persistent atrial fibrillation and heart failure: results of the RACE 3 study. <i>Europace</i> , 2021, 23, 1359-1368.	0.7	11
110	Adherence and Persistence with Once-Daily vs Twice-Daily Direct Oral Anticoagulants Among Patients with Atrial Fibrillation: Real-World Analyses from the Netherlands, Italy and Germany. <i>Drugs - Real World Outcomes</i> , 2022, 9, 199-209.	0.7	11
111	Iron i.v. in heart failure: ready for implementation?. <i>European Heart Journal</i> , 2015, 36, 645-647.	1.0	10
112	Coordination of a remote mHealth infrastructure for atrial fibrillation management during COVID-19 and beyond: TeleCheck-AF. <i>International Journal of Care Coordination</i> , 2020, 23, 65-70.	0.3	10
113	Review: Contrast-enhanced magnetic resonance in the diagnosis and management of cardiac sarcoidosis. <i>Progress in Cardiovascular Diseases</i> , 2020, 63, 271-307.	1.6	10
114	Different circulating biomarkers in women and men with paroxysmal atrial fibrillation: results from the AF-RISK and RACE V studies. <i>Europace</i> , 2022, 24, 193-201.	0.7	10
115	Tissue velocity imaging of the left atrium predicts response to flecainide in patients with acute atrial fibrillation. <i>Heart Rhythm</i> , 2014, 11, 478-484.	0.3	9
116	Differentiating the effects of β^2 -adrenergic stimulation and stretch on calcium and force dynamics using a novel electromechanical cardiomyocyte model. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2020, 319, H519-H530.	1.5	9
117	Open-Label, Multicenter Study of Flecainide Acetate Oral Inhalation Solution for Acute Conversion of Recent-Onset, Symptomatic Atrial Fibrillation to Sinus Rhythm. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2022, 15, CIRCEP121010204.	2.1	8
118	Cardioversion of persistent atrial fibrillation is associated with a 24-hour relapse gap: Observations from prolonged postcardioversion rhythm monitoring. <i>Clinical Cardiology</i> , 2018, 41, 366-371.	0.7	7
119	Personalization of injection protocols to the individual patient's blood volume and automated tube voltage selection (ATVS) in coronary CTA. <i>PLoS ONE</i> , 2018, 13, e0203682.	1.1	7
120	Rising prevalence of atrial fibrillation in the elderly population: new challenges of geriatric cardiology. <i>Europace</i> , 2019, 21, 1451-1453.	0.7	7
121	Design and rationale of DUTCH-AF: a prospective nationwide registry programme and observational study on long-term oral antithrombotic treatment in patients with atrial fibrillation. <i>BMJ Open</i> , 2020, 10, e036220.	0.8	7
122	Atrial remodeling and atrial fibrillation recurrence after catheter ablation. <i>Herz</i> , 2021, 46, 312-317.	0.4	7
123	Integrated Chronic Care Management For Patients With Atrial Fibrillation - A Rationale For Redesigning Atrial Fibrillation Care. <i>Journal of Atrial Fibrillation</i> , 2015, 7, 1177.	0.5	7
124	Association between comorbidities and left and right atrial dysfunction in patients with paroxysmal atrial fibrillation: Analysis of AF-RISK. <i>International Journal of Cardiology</i> , 2022, 360, 29-35.	0.8	7
125	The role of standard non-ECG gated chest CT in cardiac assessment: design and rationale of the Cardiac Pathologies in standard chest CT (CaPaCT) study. <i>European Radiology Experimental</i> , 2018, 2, 9.	1.7	6
126	Cardiac Inflammation Impedes Response to Cardiac Resynchronization Therapy in Patients With Idiopathic Dilated Cardiomyopathy. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2020, 13, e008727.	2.1	6

#	ARTICLE	IF	CITATIONS
127	A novel framework for noninvasive analysis of short-term atrial activity dynamics during persistent atrial fibrillation. <i>Medical and Biological Engineering and Computing</i> , 2020, 58, 1933-1945.	1.6	6
128	Pulmonary vein isolation in a real-world population does not influence QTc interval. <i>Europace</i> , 2021, 23, i48-i54.	0.7	6
129	Clinical utility of rhythm control by electrical cardioversion to assess the association between self-reported symptoms and rhythm status in patients with persistent atrial fibrillation. <i>IJC Heart and Vasculature</i> , 2021, 36, 100870.	0.6	6
130	Newly discovered atrial fibrillation: who(se) care(s)?. <i>Europace</i> , 2020, 22, 677-678.	0.7	5
131	Left atrial activation and asymmetric anatomical remodeling in patients with atrial fibrillation: The relation between anatomy and function. <i>Clinical Cardiology</i> , 2021, 44, 116-122.	0.7	5
132	Pacing for repeated vagal reflex-mediated syncope: an old problem with a solution. <i>European Heart Journal</i> , 2021, 42, 517-519.	1.0	5
133	Opportunities and challenges of large-scale screening for atrial fibrillation. <i>Herzschrittmachertherapie Und Elektrophysiologie</i> , 2018, 29, 57-61.	0.3	4
134	Cardiovascular magnetic resonance accurately detects obstructive coronary artery disease in suspected non-ST elevation myocardial infarction: a sub-analysis of the CARMENTA Trial. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2021, 23, 40.	1.6	4
135	The year in cardiovascular medicine 2020: arrhythmias. <i>European Heart Journal</i> , 2021, 42, 499-507.	1.0	4
136	Long-term outcome of targeted therapy of underlying conditions in patients with early persistent atrial fibrillation and heart failure: data of the RACE 3 trial. <i>Europace</i> , 2022, 24, 910-920.	0.7	4
137	Primary prevention of atrial fibrillation by statins: still unresolved?. <i>European Heart Journal</i> , 2009, 30, 2302-2303.	1.0	3
138	T-wave Right Slope Provides a New Angle in the Prediction of Drug-Induced Ventricular Arrhythmias. <i>Cardiovascular Drugs and Therapy</i> , 2015, 29, 411-413.	1.3	3
139	The year in cardiovascular medicine 2020: arrhythmias. <i>Cardiologia Croatica</i> , 2021, 16, 107-116.	0.0	3
140	The year in cardiovascular medicine 2021: arrhythmias. <i>European Heart Journal</i> , 2022, 43, 1191-1197.	1.0	3
141	Contact forces during hybrid atrial fibrillation ablation: an in vitro evaluation. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2016, 45, 189-197.	0.6	2
142	Undersensing, asynchronous pacing, and ventricular fibrillation. <i>Europace</i> , 2019, 21, 1078-1078.	0.7	2
143	Characteristics of patients with atrial fibrillation prescribed edoxaban in Belgium and The Netherlands: insights from the ETNA-AF-Europe study. <i>Acta Cardiologica</i> , 2021, 76, 431-439.	0.3	2
144	Poor anticoagulation relates to extended access times for cardioversion and is associated with long-term major cardiac and cerebrovascular events. <i>International Journal of Cardiology</i> , 2016, 225, 337-341.	0.8	1

#	ARTICLE	IF	CITATIONS
145	Risk stratification and role for additional diagnostic testing in patients with acute chest pain and normal high-sensitivity cardiac troponin levels. <i>PLoS ONE</i> , 2018, 13, e0203506.	1.1	1
146	Adenosine usage during AF ablation in Europe and selected long-term findings from the ESC-EHRA EORP Atrial Fibrillation Ablation Long-Term registry. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2021, 60, 395-406.	0.6	1
147	To drive or NOT to drive: that's the question after ICD implantation. <i>European Heart Journal</i> , 2021, 42, 3538-3540.	1.0	1
148	Targeted Temperature Management in Out-of-Hospital Cardiac Arrest With Shockable Rhythm. <i>Critical Care Medicine</i> , 2021, Publish Ahead of Print, .	0.4	1
149	The ABLA-BOX: An in Vitro Module of Hybrid Atrial Fibrillation Ablation. <i>Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery</i> , 2016, 11, 201-209.	0.4	1
150	Contrast-enhanced cardiac Magnetic Resonance: distinction between cardiac sarcoidosis and infarction scar. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2017, 34, 307-314.	0.2	1
151	Efficacy and safety of dronedarone versus placebo in patients with atrial fibrillation stratified according to renal function: Post hoc analyses of the EURIDIS/ADONIS trials. <i>Clinical Cardiology</i> , 2022, 45, 101-109.	0.7	1
152	Letter by van Kimmenade et al Regarding Article, "Urinary N-Terminal Prohormone Brain Natriuretic Peptide Excretion in Patients With Chronic Heart Failure". <i>Circulation</i> , 2010, 121, e242; author reply e243.	1.6	0
153	Letter by Maesen et al Regarding Article, "Randomized Controlled Trial of Surgical Versus Catheter Ablation for Paroxysmal and Early Persistent Atrial Fibrillation". <i>Circulation: Arrhythmia and Electrophysiology</i> , 2019, 12, e007088.	2.1	0
154	Electrical cardioversion of atrial fibrillation and atrial flutter: manoeuvres and tips to increase its effectiveness" Authors' reply. <i>Europace</i> , 2020, 22, 1602-1602.	0.7	0
155	Emergency department cardioversion of acute atrial fibrillation. <i>Lancet, The</i> , 2020, 396, 884-885.	6.3	0
156	A Novel Biomarker Model for Detecting Patients With Atrial Fibrillation: A Development and Validation Study. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
157	Does pulmonary vein isolation prolong QT-interval?" Authors' reply. <i>Europace</i> , 2021, 23, 2046-2047.	0.7	0
158	Understanding the effects of heart beat irregularity on ventricular function in human atrial fibrillation: simulation models may help to untie the knot" Authors' reply. <i>Europace</i> , 2021, 23, 1869.	0.7	0
159	Corrected QT interval prolongation after ganglionated plexus ablation: myth or reality?" Authors' reply. <i>Europace</i> , 2021, 23, 2047-2048.	0.7	0
160	Atrial function in paroxysmal AF patients with and without heart failure with preserved ejection fraction: data from the AF-RISK study. <i>American Heart Journal</i> , 2021, 244, 36-41.	1.2	0
161	Cost Analysis From a Randomized Comparison of Immediate Versus Delayed Angiography After Cardiac Arrest. <i>Journal of the American Heart Association</i> , 2022, 11, e022238.	1.6	0
162	New-onset perioperative atrial fibrillation in cardiac surgery patients: transient trouble or persistent problem?" Authors' reply. <i>Europace</i> , 2021, , .	0.7	0